<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05622929</url>
  </required_header>
  <id_info>
    <org_study_id>CKJX839A1BR05R</org_study_id>
    <secondary_id>63520022.6.1001.0071</secondary_id>
    <nct_id>NCT05622929</nct_id>
  </id_info>
  <brief_title>Cluster Randomized Trial of a Digital Quality Improvement Intervention on LDLCholesterol Control</brief_title>
  <acronym>SAPPHIRE-LDL</acronym>
  <official_title>A Pragmatic Cluster Randomized Trial to Assess the Effect of a Digitally Enabled Quality Improvement Intervention on LDL Cholesterol Control in Atherosclerotic Established Cardiovascular Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Israelita Albert Einstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>epHealth primary care solutions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Israelita Albert Einstein</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Elevation in low density lipoprotein (LDL) cholesterol (LDL-C) is a causal risk factor for&#xD;
      atherosclerotic established cardiovascular disease (ASCVD). Reduction of LDL-C with statins&#xD;
      has been clearly demonstrated as a robust and cost-effective way of reducing the burden of&#xD;
      ASCVD in individuals at risk. ASCVD is the leading cause of death and disability in Brazil&#xD;
      and therefore prevention guidelines recommend LDL-C reduction with the aim of reducing&#xD;
      disease burden in individuals at risk. Studies have shown a clear hiatus on awareness and&#xD;
      treatment of cholesterol in Brazil. Thus, it became imperative to develop knowledge&#xD;
      translation projects aiming at bridging the gap between science and clinical practice and&#xD;
      ultimately leading to better outcomes. Cluster randomized clinical trials are the highest&#xD;
      quality type of clinical research to test educational and active interventions aimed at&#xD;
      changing behaviors or clinical practices. Therefore, this study is a pragmatic cluster&#xD;
      randomized trial to assess the effect of a digitally enabled quality improvement intervention&#xD;
      on LDL-C control in atherosclerotic established cardiovascular disease (ASCVD) patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Elevation in low density lipoprotein (LDL) cholesterol (LDL-C) is a causal risk factor for&#xD;
      atherosclerotic established cardiovascular disease (ASCVD). Reduction of LDL-C with statins&#xD;
      has been clearly demonstrated as a robust and cost-effective way of reducing the burden of&#xD;
      ASCVD in individuals at risk. ASCVD is the leading cause of death and disability in Brazil&#xD;
      and therefore prevention guidelines recommend LDL-C reduction with the aim of reducing&#xD;
      disease burden in individuals at risk. Studies have shown a clear hiatus on awareness and&#xD;
      treatment of cholesterol in Brazil. Thus, it became imperative to develop knowledge&#xD;
      translation projects aiming at bridging the gap between science and clinical practice and&#xD;
      ultimately leading to better outcomes. Cluster randomized clinical trials are the highest&#xD;
      quality type of clinical research to test educational and active interventions aimed at&#xD;
      changing behaviors or clinical practices.To our knowledge, data from this study will be&#xD;
      crucial to leverage LDL-C treatment in Brazil, considering efforts to improve population&#xD;
      health. The present study represents one of the first trials testing a quality improvement&#xD;
      (QI) intervention targeted to LDL-C reduction in ASCVD patients conducted in a middle-income&#xD;
      country. These results will address whether the proposed QI intervention is feasible and&#xD;
      effective in these settings. Therefore, this study is a pragmatic cluster randomized trial to&#xD;
      assess the effect of a digitally enabled QI intervention on LDL-C control in ASCVD patients.&#xD;
      This study will have 2 phases. Phase 1 will be an observational phase prior to randomization&#xD;
      of clusters with the objective to assess the baseline LDL-C levels achieved for target&#xD;
      patients. Phase 2 will be an interventional phase, in which clusters will be randomized to&#xD;
      the digitally enabled quality improvement intervention or usual care, with the objective to&#xD;
      assess the effect of a digitally enabled QI intervention on control of LDL-C levels in ASCVD&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2023</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Cluster randomized clinical trial</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: LDL-C levels</measure>
    <time_frame>Baseline</time_frame>
    <description>LDL-C levels measured at a single visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: LDL-C</measure>
    <time_frame>12 months</time_frame>
    <description>LDL-C levels measured at the end of follow up of Phase 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Prescribed lipid-lowering therapy</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of patients on prescribed lipid-lowering therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Prescribed combination lipid-lowering therapy</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of patients on prescribed combination lipid-lowering therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Prescribed intensive lipid-lowering therapy</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of patients on prescribed intensive lipid-lowering therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Prescription of high intensity statins</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of prescription of high intensity statins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Prescription of ezetimibe</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of prescription of ezetimibe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Prescription of PCSK9 inhibitors</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of prescription of PCSK9 inhibitors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: LDL-C &lt; 50 mg/dL</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of patients with LDL-C &lt; 50 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Prescribed lipid-lowering therapy</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients on prescribed lipid-lowering therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Prescribed combination lipid-lowering therapy</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients on prescribed combination lipid-lowering therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Prescribed intensive lipid-lowering therapy</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients on prescribed intensive lipid-lowering therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Prescription of high intensity statins</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of prescription of high intensity statins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Prescription of moderate intensity statins</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of prescription of moderate intensity statins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Prescription of low intensity statins</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of prescription of low intensity statins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Prescription of ezetimibe</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of prescription of ezetimibe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Prescription of PCSK9 inhibitors</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of prescription of PCSK9 inhibitors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: LDL-C &lt; 50 mg/dL</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients with LDL-C &lt; 50 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: LDL-C relative change</measure>
    <time_frame>12 months</time_frame>
    <description>Change in LDL-C relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: LDL-C reduction of ≥50%</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients with LDL-C reduction of ≥50% relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Barriers for drug prescription</measure>
    <time_frame>12 months</time_frame>
    <description>Barriers for drug prescription at the system (cluster) and physician level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Adherence to prescribed lipid-lowering therapy</measure>
    <time_frame>12 months</time_frame>
    <description>Patient´s adherence to prescribed lipid-lowering therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Barriers for drug adherence</measure>
    <time_frame>12 months</time_frame>
    <description>Patient´s barriers for drug adherence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Intolerance to Statins</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients with intolerance to Statins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: 5P-MACE (Major Cardiovascular Events)</measure>
    <time_frame>12 months</time_frame>
    <description>Composite endpoint of time to first occurrence of a major cardiovascular event 5P-MACE including cardiovascular deaths. non-fatal stroke or transient ischemic attack (TIA), non-fatal myocardial infarction, hospitalization for unstable angina, or coronary revascularization, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: 3P-MACE (Major Cardiovascular Events)</measure>
    <time_frame>12 months</time_frame>
    <description>Composite endpoint of time to first occurrence of a major cardiovascular event 3P-MACE including cardiovascular deaths, non-fatal stroke or TIA, or non-fatal myocardial infarction, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Cardiovascular death</measure>
    <time_frame>12 months</time_frame>
    <description>Time to cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Death from any cause</measure>
    <time_frame>12 months</time_frame>
    <description>Time to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Myocardial infarction</measure>
    <time_frame>12 months</time_frame>
    <description>Time to first myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Stroke</measure>
    <time_frame>12 months</time_frame>
    <description>Time to first stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Coronary revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>Time to first coronary revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Total deaths</measure>
    <time_frame>12 months</time_frame>
    <description>Total deaths within 12 months from inclusion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2800</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Atherosclerosis</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Real-world evidence (RWE) platform to provide data on their clinical practice + usual care + Digitally-enabled Multifaceted Quality Improvement Intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RWE platform to provide data on their clinical practice + usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Digitally-enabled Multifaceted Quality Improvement Intervention</intervention_name>
    <description>Digitally-enabled multifaceted strategy in addition to access to a RWE platform to provide clinical data. The digitally-enabled multifaceted strategy will include various tools that will provide support to the health professionals responsible for treating ASCVD patients in each center as well as patients, including:&#xD;
Knowledge of effective lipid lowering therapies&#xD;
Clinical decision support&#xD;
Audit and feedback on adherence to optimal clinical management&#xD;
Audit and feedback on LDL-C control</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Health professionals responsible for treating ASCVD patients in each center will continue to provide usual care to ASCVD patients in addition to provide data through a RWE platform.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patient Eligibility Criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Capable of using a smartphone with iOS or Android System AND&#xD;
&#xD;
          -  Established ASCVD, including:&#xD;
&#xD;
               1. Coronary Artery Disease (CAD):&#xD;
&#xD;
                    -  Prior myocardial infarction&#xD;
&#xD;
                    -  Prior coronary revascularization - percutaneous coronary intervention (PCI)&#xD;
                       or coronary artery bypass graft (CABG)&#xD;
&#xD;
                    -  Angiographic or computerized tomography (CT)-imaging evidence of coronary&#xD;
                       atherosclerosis (≥ 50% stenosis in at least one major epicardial coronary&#xD;
                       artery)&#xD;
&#xD;
               2. Stroke:&#xD;
&#xD;
                  • Prior ischemic stroke thought not to be caused by an embolic cause (e.g.,&#xD;
                  atrial fibrillation, valvular heart disease or mural thrombus)&#xD;
&#xD;
               3. Peripheral Artery Disease (PAD):&#xD;
&#xD;
                    -  Prior documentation of a resting ankle-brachial index ≤ 0.9&#xD;
&#xD;
                    -  History of prior percutaneous or surgical revascularization of an iliac,&#xD;
                       femoral, or popliteal artery&#xD;
&#xD;
                    -  Prior non-traumatic amputation of a lower extremity due to peripheral artery&#xD;
                       disease&#xD;
&#xD;
                    -  History of prior percutaneous or surgical carotid artery revascularization&#xD;
&#xD;
                    -  Carotid Stenosis &gt; 50% on prior angiography or ultrasound AND&#xD;
&#xD;
          -  Provision of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a recent cardiovascular event, less than 3 months prior to study&#xD;
             inclusion&#xD;
&#xD;
          -  Patients with LDL-C ≤ 70 mg/dL&#xD;
&#xD;
          -  Current participation in other clinical trials involving lipid lowering treatments&#xD;
&#xD;
          -  Patients that do not consent to trial participation&#xD;
&#xD;
        Cluster Eligibility Criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatient Clinics from public or private hospitals OR, Private Practices, which&#xD;
             assist patients with previous ASCVD on secondary prevention that provide a&#xD;
             unit/institution authorization form for participation in the trial AND&#xD;
&#xD;
          -  Minimum monthly volume of 20 ASCVD patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clusters that do not provide the unit/institution authorization form.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Julia Machline-Carrion, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>epHealth</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karla E Santo, PhD</last_name>
    <phone>+55 11 2151-5915</phone>
    <email>karla.santo@einstein.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital da Bahia</name>
      <address>
        <city>Salvador</city>
        <state>BA</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianna Dracoulakis</last_name>
    </contact>
    <investigator>
      <last_name>Marianna Dracoulakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Lúcia</name>
      <address>
        <city>Poços De Caldas</city>
        <state>MG</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederico Dall'Orto</last_name>
    </contact>
    <investigator>
      <last_name>Frederico Dall'Orto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital e Maternidade Angelina Caron</name>
      <address>
        <city>Campina Grande Do Sul</city>
        <state>PR</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalton Precoma</last_name>
    </contact>
    <investigator>
      <last_name>Dalton Precoma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Hans Dieter Schmidt</name>
      <address>
        <city>Joinville</city>
        <state>SC</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Conrado HOFFMANN FILHO</last_name>
    </contact>
    <investigator>
      <last_name>Conrado HOFFMANN FILHO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Clínica do Coração</name>
      <address>
        <city>Aracaju</city>
        <state>SE</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Silveira</last_name>
    </contact>
    <investigator>
      <last_name>Fabio Silveira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário São Francisco de Assis</name>
      <address>
        <city>Bragança Paulista</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Murillo Antunes</last_name>
    </contact>
    <investigator>
      <last_name>Murillo Antunes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clínica de Campinas</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Francisco Saraiva</last_name>
    </contact>
    <investigator>
      <last_name>Jose Francisco Saraiva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericórdia de Marilia</name>
      <address>
        <city>Marília</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Andrade</last_name>
    </contact>
    <investigator>
      <last_name>Pedro Andrade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos Fernando Malzoni</name>
      <address>
        <city>Matão</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesar Minelli</last_name>
    </contact>
    <investigator>
      <last_name>Cesar Minelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2022</study_first_posted>
  <last_update_submitted>March 21, 2023</last_update_submitted>
  <last_update_submitted_qc>March 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiovascular diseases</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Dyslipidemias</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

